WO2009085226A3 - Inhibiteurs des kinases de type cdc2 (clk) et leurs procédés d'utilisation - Google Patents

Inhibiteurs des kinases de type cdc2 (clk) et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2009085226A3
WO2009085226A3 PCT/US2008/013927 US2008013927W WO2009085226A3 WO 2009085226 A3 WO2009085226 A3 WO 2009085226A3 US 2008013927 W US2008013927 W US 2008013927W WO 2009085226 A3 WO2009085226 A3 WO 2009085226A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
clk
cdc2
methods
Prior art date
Application number
PCT/US2008/013927
Other languages
English (en)
Other versions
WO2009085226A2 (fr
Inventor
Robert B. Perni
Jean Bemis
Joseph J. Nunes
Bruce G. Szczepankiewicz
Original Assignee
Sirtris Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals, Inc. filed Critical Sirtris Pharmaceuticals, Inc.
Publication of WO2009085226A2 publication Critical patent/WO2009085226A2/fr
Publication of WO2009085226A3 publication Critical patent/WO2009085226A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés qui sont des composés inhibant les kinases de type CDC2 (CLK) et leurs procédés d'utilisation. Les composés inhibant les CLK peuvent être utilisés pour augmenter la durée de vie d'une cellule, et traiter et/ou prévenir un large éventail de maladies et de troubles comprenant, par exemple, des maladies ou des troubles liés à l'âge ou le stress, le diabète, l'obésité, les maladies neurodégénératives, les maladies cardiovasculaires, les troubles de coagulation du sang, l'inflammation, les troubles oculaires, et/ou traiter également des maladies ou troubles qui découleraient d'une activité mitochondriale augmentée. L'invention concerne également des compositions comprenant un composé inhibant les CLK en association avec un autre agent thérapeutique.
PCT/US2008/013927 2007-12-21 2008-12-19 Inhibiteurs des kinases de type cdc2 (clk) et leurs procédés d'utilisation WO2009085226A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US896407P 2007-12-21 2007-12-21
US61/008,964 2007-12-21

Publications (2)

Publication Number Publication Date
WO2009085226A2 WO2009085226A2 (fr) 2009-07-09
WO2009085226A3 true WO2009085226A3 (fr) 2009-11-05

Family

ID=40386340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/013927 WO2009085226A2 (fr) 2007-12-21 2008-12-19 Inhibiteurs des kinases de type cdc2 (clk) et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2009085226A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5425891B2 (ja) 2008-05-01 2014-02-26 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節薬としてのキノリンおよび関連する類似体
CN104193740A (zh) 2008-07-03 2014-12-10 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
RU2519779C2 (ru) 2008-09-29 2014-06-20 Сертрис Фармасьютикалз Инк. Хиназолинон, хинолон и родственные аналоги в качестве модуляторов сиртуина
WO2011041655A1 (fr) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dérivés de la quinazolin-4-amine; et méthodes d'utilisation
WO2011059839A1 (fr) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Pyridines bicycliques et analogues en tant que modulateurs de la sirtuine
EP3085698B1 (fr) 2013-12-18 2019-11-13 Kyoto University Composé associé à la douleur et composition médicinale
US20170281607A1 (en) * 2016-04-01 2017-10-05 University Of Limerick Pharmaceutical compositions and methods for the treatment of diabetes
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
WO2018064545A1 (fr) * 2016-09-30 2018-04-05 Sri International Inhibiteurs doubles de clk/cdk1 destinés au traitement du cancer
EP3813826A4 (fr) * 2018-06-26 2022-07-06 BioSplice Therapeutics, Inc. Méthodes de traitement du cancer à l'aide d'un inhibiteur de clk

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171026A1 (en) * 2004-01-09 2005-08-04 Tokyo Medical And Dental University Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171026A1 (en) * 2004-01-09 2005-08-04 Tokyo Medical And Dental University Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction

Also Published As

Publication number Publication date
WO2009085226A2 (fr) 2009-07-09

Similar Documents

Publication Publication Date Title
WO2009085226A3 (fr) Inhibiteurs des kinases de type cdc2 (clk) et leurs procédés d'utilisation
WO2006105440A3 (fr) Nicotinamide riboside et analogues
WO2007102861A3 (fr) Modulateurs de kinases de type cdc2 (clks) et leurs procédés d'utilisation
WO2009134973A8 (fr) Quinoléines et analogues apparentés en tant que modulateurs de sirtuine
WO2006094209A3 (fr) Modulateurs de sirtuine a amide n-benzimidazolylalkyle substitue
WO2006078941A3 (fr) Nouveaux composes d'activation de la sirtuine et procedes d'utilisation associes
WO2010037127A8 (fr) Analogues de chroménone en tant que modulateurs de sirtuine
MY149316A (en) Sirtuin modulating imidazohiazole compounds
WO2006094210A3 (fr) Modulateurs de sirtuine de tetrahydroquinoxalinone
IN2012DN03799A (fr)
MX2010012961A (es) Imidazopiridina y analogos relacionados como moduladores de sirtuina.
UA104447C2 (uk) Тіазолопіридинові сполуки, що модулюють сиртуїн
MX2010004965A (es) Derivados de amida como moduladores de la sirtuina.
WO2007019344A8 (fr) Dérivés d'imidazo [2,1-b] thiayole en tant que modulateurs de sirtuine
MX2011006475A (es) Ftalazinona y analogos relacionados como moduladores de sirtuina.
MX2011006084A (es) Isoindolinona y analogos relacionados como moduladores de sirtuina.
WO2006094237A3 (fr) Modulateurs de la sirtuine a base d'acridine et de quineoline
WO2009061453A8 (fr) Thiazolopyridines solubilisées
WO2006094246A3 (fr) Modulateurs de sirtuine a base de n-arylmethyl benzamide
MX2011009213A (es) Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina.
WO2009064802A3 (fr) Inhibiteurs de phosphatidyl-inositol 3-kinase delta humaine
WO2010029089A3 (fr) Polythérapie pour le traitement du diabète et des états pathologiques apparentés
WO2007130383A3 (fr) Compositions et traitements utilisant des pyridazines et des secrétases
WO2007022225A3 (fr) Composes nitres cycliques, compositions pharmaceutiques contenant ces composes et leurs applications
WO2008033562A3 (fr) Composés inhibiteurs de kinases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08867162

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08867162

Country of ref document: EP

Kind code of ref document: A2